A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

PHASE3RecruitingINTERVENTIONAL

Enrollment

4,800

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

January 31, 2025

Conditions

COVID-19

Interventions

BIOLOGICAL

Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

BIOLOGICAL

Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

BIOLOGICAL

Placebo

boost with saline

Trial Locations (1)

RECRUITING

Jiangsu Provincial Center for Disease Control and Prevention, Nanjing

All Listed Sponsors

collaborator

WestVac Biopharma (Guangzhou) Co., Ltd.

UNKNOWN

lead

WestVac Biopharma Co., Ltd.

INDUSTRY